Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, VAY736, -
CVAY736A2302
Phase 3 small_molecule active
Quick answer
Placebo to VAY736 150 mg/1 mL Solution for injection in pre-filled syringe, VAY736, - for Sjögren’s Syndrome is a Phase 3 program (small_molecule) at Novartis Ophthalmics Europe with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novartis Ophthalmics Europe
- Indication
- Sjögren’s Syndrome
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active